Geode Capital Management
EIGR

Geode Capital Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Geode Capital Management’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-12,652
Closed -$63.3K – 4699
2024
Q1 		$63.3K Sell
12,652
-5
-0% -$31 ﹤0.01% 4270
2023
Q4 		$85.3K Hold
12,657
– – ﹤0.01% 4231
2023
Q3 		$116K Buy
12,657
+10
+0.1% +$201 ﹤0.01% 4195
2023
Q2 		$267K Sell
12,647
-13,611
-52% -$419K ﹤0.01% 3911
2023
Q1 		$707K Buy
26,258
+914
+4% +$42.5K ﹤0.01% 3514
2022
Q4 		$897K Buy
25,344
+761
+3% +$91.4K ﹤0.01% 3395
2022
Q3 		$5.55M Buy
24,583
+1,534
+7% +$377K ﹤0.01% 2612
2022
Q2 		$4.36M Buy
23,049
+1,863
+9% +$376K ﹤0.01% 2782
2022
Q1 		$5.28M Buy
21,186
+860
+4% +$136K ﹤0.01% 2770
2021
Q4 		$3.16M Buy
20,326
+66
+0.3% +$12.8K ﹤0.01% 3142
2021
Q3 		$4.06M Buy
20,260
+312
+2% +$74.2K ﹤0.01% 3030
2021
Q2 		$5.1M Buy
19,948
+1,248
+7% +$311K ﹤0.01% 2895
2021
Q1 		$4.96M Buy
18,700
+3,301
+21% +$1.04M ﹤0.01% 2795
2020
Q4 		$5.68M Buy
15,399
+2,353
+18% +$675K ﹤0.01% 2537
2020
Q3 		$3.19M Buy
13,046
+1,374
+12% +$427K ﹤0.01% 2637
2020
Q2 		$3.36M Buy
11,672
+831
+8% +$245K ﹤0.01% 2544
2020
Q1 		$2.21M Buy
10,841
+752
+7% +$240K ﹤0.01% 2619
2019
Q4 		$4.51M Buy
10,089
+307
+3% +$109K ﹤0.01% 2519
2019
Q3 		$3.01M Buy
9,782
+140
+1% +$45.5K ﹤0.01% 2690
2019
Q2 		$3.07M Buy
9,642
+5,545
+135% +$1.92M ﹤0.01% 2678
2019
Q1 		$1.72M Buy
4,097
+604
+17% +$242K ﹤0.01% 2939
2018
Q4 		$1.06M Buy
3,493
+904
+35% +$292K ﹤0.01% 3090
2018
Q3 		$931K Hold
2,589
– – ﹤0.01% 3249
2018
Q2 		$947K Buy
2,589
+1,819
+236% +$648K ﹤0.01% 3206
2018
Q1 		$227K Hold
770
– – ﹤0.01% 3652
2017
Q4 		$322K Hold
770
– – ﹤0.01% 3515
2017
Q3 		$253K Hold
770
– – ﹤0.01% 3594
2017
Q2 		$182K Sell
770
-303
-28% -$68.8K ﹤0.01% 3719
2017
Q1 		$368K Buy
1,073
+180
+20% +$62K ﹤0.01% 3430
2016
Q4 		$311K Buy
893
+8
+0.9% +$2.93K ﹤0.01% 3442
2016
Q3 		$355K Buy
885
+550
+164% +$281K ﹤0.01% 3385
2016
Q2 		$199K Buy
+335
New +$204K ﹤0.01% 3601
2016
Q1 		– Sell
-131
Closed -$86K – 4116
2015
Q4 		$86K Hold
131
– – ﹤0.01% 3918
2015
Q3 		$61K Hold
131
– – ﹤0.01% 3990
2015
Q2 		$74K Hold
131
– – ﹤0.01% 3819
2015
Q1 		$1.11M Buy
131
+10
+8% +$87.4K ﹤0.01% 2818
2014
Q4 		$1.07M Hold
121
– – ﹤0.01% 2798
2014
Q3 		$570K Buy
121
+73
+152% +$386K ﹤0.01% 3103
2014
Q2 		$343K Sell
48
-9
-16% -$45K ﹤0.01% 3328
2014
Q1 		$307K Buy
+57
New +$269K ﹤0.01% 3352

Other funds holding EIGR

PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Geode Capital Management's EIGR Position: Q2 2024 in Review

Geode Capital Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2024, closing a stake of 12,652 shares — an estimated $63.3K sold.

Geode Capital Management first reported a position in EIGR in Q1 2014 and held it in 40 quarters. The position peaked at $5.68M in Q4 2020. 2 funds tracked by Wall St. Rank hold EIGR as of Q2 2024.

  • Geode Capital Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
  • Geode Capital Management sold 12,652 Eiger BioPharmaceuticals, Inc. shares in Q2 2024, an estimated $63.3K.
  • Geode Capital Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2014 and held it in 40 quarters.
  • Geode Capital Management's Eiger BioPharmaceuticals, Inc. position peaked at $5.68M in Q4 2020.
  • 2 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2024.

Based on Geode Capital Management's 13F filing for Q2 2024, filed 9 Aug 2024.